Deepak Nitrite Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 24 May 2026 | Chemicals & Petrochemicals | Market Cap: ₹23.7K Cr

Advanced Intermediates segment expects healthy volume growth supported by stable domestic demand and improving pricing environment. FY27 is expected to show a stronger margin profile and improving earnings trends compared to FY26, driven by new downstream products, especially in agri-chemicals and advanced intermediates.

From Deepak Nitrite Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹1,747

Market Cap

₹23.7K Cr

P/E Ratio

29.9

How does Deepak Nitrite Ltd rank in Chemicals & Petrochemicals?

Compare Deepak Nitrite Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Deepak Nitrite Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2.1K Cr, net profit ₹220 Cr.

Full financials →

📊 Revenue & Sales Performance

→Advanced Intermediates segment expects healthy volume growth supported by stable domestic demand and improving pricing environment. (Page 5 and 11)
→Phenolics segment anticipates better performance in Q1 FY27 over Q4 FY26 with high plant efficiencies and no feedstock constraints. (Page 12)
→New products including fluorinated molecules and downstream chemistries to contribute to revenue from Q3 FY27 onwards. (Page 7 and 12)
→Expansion projects like polycarbonate and agrochemical intermediates on track to support product diversification and margin improvement. (Pages 4, 6)
→Market conditions to remain influenced by geopolitical factors and Chinese supply dynamics, but company expects margin improvement and volume growth in FY27. (Page 12)
→Continued focus on portfolio optimization, deeper customer engagements, and cost efficiencies to drive long-term competitiveness and revenue growth. (Page 5 and 11)

📈 Profitability & Margins

→FY27 is expected to show a stronger margin profile and improving earnings trends compared to FY26, driven by new downstream products, especially in agri-chemicals and advanced intermediates.
→Continuous product expansion, portfolio optimization, and cost efficiencies are anticipated to support growth and margin improvement.
→Integrated manufacturing and backward integration are set to boost structural margin benefits and improve competitiveness.
→New projects like the polycarbonate facility, MIBK and MIBC plants, and fluorinated molecules are on track to start commercial production in FY27, contributing to revenue and profit growth.
→Management anticipates stable or improving profitability in Q1 FY27 compared to Q4 FY26, driven by improved spreads and downstream demand recovery.
→Strategic initiatives and improved feedstock procurement reduce volatility risk, supporting sustainable margin expansion.
→Dividend and capital allocation policy indicates commitment to long-term value creation alongside growth.
→Overall, earnings, operating profits, and EPS are expected to grow in FY27 on the back of operational excellence and strategic expansions.

🏗️ Capital Expenditure Plans

→Total announced project capex is around INR 11,000 crore, including multiple projects.
→The Polycarbonate (PC) project is expected to be commissioned by June 2028.
→Strategic investments are progressing as planned to support product diversification, import substitution, and margin improvement.
→A dedicated on-site HyCO plant at the Dahej facility is being established via a long-term agreement with Praxair India under a Build-Own-Operate model to enhance execution visibility and reduce upfront investment.
→Initiatives include expansions into downstream chemistries and integrated manufacturing capabilities.
→New products including fluorinated molecules (INR 220 crore capex) have started production, targeting commercial scale by Q3 FY27.
→MIBK/MIBC plants are nearing mechanical completion with commissioning expected by late Q1 or early Q2 FY27.
→Funding is through a mix of 60% bank debt and 40% equity; debt tie-ups are in place with equity infusion underway.

💰 Fundraising & Capital Structure

→Total announced project capex is around INR 11,000 crore, covering multiple projects.
→Funding will be in a 60:40 debt-equity ratio.
→Bank loans for debt portion are already tied up.
→Equity contribution has commenced; once 25% equity (of the 40%) is infused, debt drawdown will begin.
→The company is generating sufficient internal cash flows to fund equity.
→If additional funds are needed beyond planned bank loans, the company may approach capital markets.
→Overall, funding is not expected to be an issue given cash generation and banking arrangements.

📋 Order Book & Pipeline

The provided transcript from the Deepak Nitrite Limited Q4 & FY26 Earnings Conference Call does not explicitly mention the current or expected order book or pending orders details. Key takeaways related to business outlook and operations include: - Strong demand with stable or improving productivity in various plants. - New products in advanced stages of customer approval, expected to contribute from Q3 FY27. - Polycarbonate project on track for commissioning by June 2028. - Positive tailwinds expected due to regulatory changes in China impacting nitration capacities. - Focus on stable supply supporting customers' downstream expansions. - Financial and operational metrics suggest improving margins and volumes, supporting a robust business outlook. For precise current order book or pending orders data, investor relations contact (Mr. Somsekhar Nanda or Mr. Gopal Thakkar) may be approached as suggested by management.

Key Metrics

What Deepak Nitrite Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

NOCIL (Q4 FY26)
The Rs.130 crores capex includes some intermediates and is largely for captive consumption, with part allocated to finished goods. Key concall takeaways from…
Indo Borax & Chemicals Ltd (Q4 FY26)
175 crores revenue in the previous financial year and Rs. Key concall takeaways from Indo Borax & Chemicals Ltd's Q4 FY26 earnings call — and how it ranks…
Rossari Biotech (Q4 FY26)
50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments. Key concall takeaways from Rossari…
Pidilite Inds. (Q4 FY26)
Underlying volume growth (UVG) averaged over 9% per quarter last year, with a ~200 bps increase in FY '25; the company plans to continue lifting UVG…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Deepak Nitrite Ltd Q4 FY26 results?

What is Deepak Nitrite Ltd share price analysis?

Deepak Nitrite Ltd currently shows a neutral. The stock trades at a P/E of 29.9 with a market cap of ₹23,687 Cr. Investors should review the full earnings analysis for detailed insights.

Is Deepak Nitrite Ltd planning capital expenditure?

Total announced project capex is around INR 11,000 crore, including multiple projects.

Keep Deepak Nitrite Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.